Alpha Cognition (NASDAQ:ACOG) Downgraded by Wall Street Zen to “Sell”

Alpha Cognition (NASDAQ:ACOG) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alpha Cognition in a research report on Friday, May 16th.

Alpha Cognition Price Performance

ACOG stock opened at $8.00 on Friday. The company has a 50 day simple moving average of $9.64 and a 200 day simple moving average of $7.40. The stock has a market cap of $128.16 million, a price-to-earnings ratio of -5.00 and a beta of 2.72. Alpha Cognition has a 1 year low of $3.75 and a 1 year high of $11.54.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.19). The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $2.32 million.

Institutional Investors Weigh In On Alpha Cognition

Institutional investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL bought a new stake in Alpha Cognition during the 4th quarter worth approximately $412,000. Villere ST Denis J & Co. LLC grew its holdings in Alpha Cognition by 201.0% during the 1st quarter. Villere ST Denis J & Co. LLC now owns 71,778 shares of the company’s stock worth $363,000 after acquiring an additional 47,928 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Alpha Cognition during the 4th quarter worth approximately $1,284,000. Bleichroeder LP bought a new stake in shares of Alpha Cognition in the 4th quarter valued at $1,024,000. Finally, Salem Investment Counselors Inc. bought a new stake in shares of Alpha Cognition in the 1st quarter valued at $230,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.